Investors

NEWS & UPDATES

Press Releases

April 28, 2026

Kestrel Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies

Kestrel Therapeutics announced the first patient has been dosed in its Phase 1 clinical trial evaluating KST-6051 in patients with KRAS-driven cancers.

Read More

March 5, 2026

Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trials

Kestrel is advancing KST-6051 into the clinic and expects to initiate a first-in-human Phase 1 dose escalation clinical trial FALCON by the end of the first quarter.

Read More

Kestrel Therapeutics has attracted funding from thought-leading investors.

Santé Logo
Cormorant logo
Section 32 Logo

Investor Inquiries